ClinicalTrials.gg
Not yet recruitingNCT07940270GCA-PANICUpdated Nov 16, 2026

Ultrasound Screening of the Aorta in Giant Cell Arteritis

An observational study in Giant Cell Arteritis (GCA), Aortic Dilatation and Aortic Aneurysm, sponsored by Esbjerg Hospital - University Hospital of Southern Denmark. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Esbjerg Hospital - University Hospital of Southern Denmark · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
102
Sex
All
01

Study summary

The goal of this observational study is to find out whether ultrasound can reliably detect dilatation and aneurysms of the aorta, the main blood vessel that carries blood from the heart to the rest of the body, in people with giant cell arteritis (GCA). GCA causes inflammation in the blood vessel walls. It can affect the aorta and increase the risk of aortic dilatation and aneurysms. Aortic dilatation is an abnormal widening of the aorta. When it becomes large, it is called an aneurysm, and can lead to serious complications.

The main questions the study aims to answer are:

How accurately can ultrasound performed by rheumatologists detect dilatation and aneurysms of the aorta compared with computed tomography (CT) angiography, which provides detailed images of the aorta?

How consistently do different rheumatologists evaluate the aorta using ultrasound?

How often is aortic dilatation and aneurysms found in people with GCA who previously had signs of inflammation in the aorta on a PET-CT scan?

Researchers will compare ultrasound measurements with CT angiography findings to assess how well ultrasound detects aortic dilatation and aneurysms.

The study will include 102 participants: 82 people with GCA and previous signs of aortic inflammation on PET-CT, 10 people with GCA and a known aortic dilatation or aneurysm, and 10 people with aortic dilatation or aneurysm not caused by inflammation.

Participants will undergo an ultrasound examination of the ascending aorta, the part of the aorta closest to the heart. Participants will also undergo CT angiography of the aorta, which uses X-rays and contrast dye to produce detailed images of the blood vessel. The ultrasound measurements will be compared with the CT angiography findings. The ultrasound evaluations of the ultrasound performing rheumatologists will be compared with evaluations of a blinded assessor.

The long-term aim is to determine whether ultrasound could be a useful, non-invasive screening method to help identify aortic dilatation and aneurysms in people with GCA.

02

Conditions studied

  • Giant Cell Arteritis (GCA)
  • Aortic Dilatation
  • Aortic Aneurysm
03

In context

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 49 are open to participants now.

This study's planned enrollment of 102 is below the median of 122 across 79 observational studies indexed under Giant Cell Arteritis.

Browse Giant Cell Arteritis studies →

Lead sponsor

Esbjerg Hospital - University Hospital of Southern Denmark is the lead sponsor of 51 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

GCA patients will be recruited from the five Rheumatology clinics of the Region of Southern Denmark (Odense University Hospital, Svendborg Hospital, Esbjerg Hospital, the Danish Hospital for Rheumatic Diseases, Lillebælt Hospital). Non-GCA patients will be recruited from the Cardiology clinic of Esbjerg Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • GCA diagnosis with initial PET-CT involvement of thoracic aorta for the "GCA without known dilatation or aneurysm of the aorta" cohort
  • Established ascending aortic dilatation or anerysm through CT or MR angiography of the aorta and a history of GCA for the "GCA with known dilatation or aneurysm of the aorta" cohort
  • Established ascending aortic dilatation or aneurysm through CT or MR angiography of the aorta and no history of vasculitis for the "Non-GCA with known dilatation or aneurysm of the aorta" cohort

Exclusion criteria

Exclusion Criteria:

  • Inability to consent
  • Inability to undergo ultrasound of the aorta
  • ≥ 40
  • Previous operation for aortic structural damage

Specifically for the "GCA without known dilatation or aneurysm of the aorta" cohort:

  • Inability to undergo CT angiography of the aorta
  • Unknown kidney function and unwillingness to have it tested before CT angiography
  • Known kidney failure (\<30ml/min/1.73m3)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
102 participants (estimated)
Patient registry
No

Groups and cohorts

  • GCA without known aortic dilatation or aneurysm but known aortic inflammation in PET-CT at debut

    GCA patients with involvement of the thoracic aorta in the initial PET-CT upon diagnosis who have or have had regular follow-ups in the Rheumatology Clinics of the Region of Southern Denmark, who do not have known aortic dilatation or aneurysm, will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta and CT angiography of the aorta. Inclusion will stop at 82 subjects.

  • GCA with known aortic dilatation or aneurysm

    GCA patients with CT or MR angiography-established dilatation or aneurysm of the thoracic aorta who have or have had regular follow-ups in the Rheumatology clinics of the Region of Southern Denmark will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects

  • Non-GCA with known aortic dilatation or aneurysm

    Patients with CT or MR angiography established dilatation or aneurysm of the thoracic aorta on a non-inflammatory basis who have regular follow-ups in the Cardiology Clinic in Esbjerg Hospital will be invited to the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of thoracic aorta ultrasound for detecting aortic dilatation and aneurysms

    The ability of ultrasound measurements of the thoracic aorta to identify aortic dilatation or aneurysms will be evaluated using CT angiography as the reference standard. A receiver operating characteristic (ROC) curve will be used to assess how well the ultrasound measurements distinguish between participants with and without aortic dilatation or aneurysms. Diagnostic performance will be summarized by calculating the area under the ROC curve (AUC).

    Time frame: At the baseline study visit.

Secondary outcomes

  1. Agreement between assessors in ultrasound measurements of the thoracic aorta

    Agreement between rheumatologists performing ultrasound examinations and an independent, blinded assessor will be evaluated by comparing their measurements of the thoracic aorta. Agreement will be quantified using the intraclass correlation coefficient (ICC), which indicates how closely the measurements agree. A two-way random-effects model assessing absolute agreement will be used (ICC\[2,1\]).

    Time frame: At the baseline study visit.

  2. Prevalence of thoracic aortic dilatation and aneurysm in GCA patients with prior FDG-PET/CT-confirmed aortic uptake

    The prevalence of thoracic aortic dilatation and aneurysm will be assessed among the patients with giant cell arteritis (GCA) and aortic FDG uptake on PET/CT at diagnosis. Thoracic aortic diameters will be measured with CT angiography and aortic dilatation and aneurysm will be classified according to prespecified diameter-based diagnostic criteria. Prevalence will be calculated as the number of participants meeting the criteria for aortic dilatation or aneurysm at the study assessment divided by the total number of this cohort's participants with evaluable CT angiography scans. Aortic dilatation and aneurysm will also be reported separately, where applicable.

    Time frame: At the baseline study visit.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Dec 2029, 31 months later.

Of 45 observational studies under Giant Cell Arteritis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartEst.
May 1, 2027
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940270
Lead sponsor
Esbjerg Hospital - University Hospital of Southern Denmark
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
May 1, 2027 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Stavros Chrysidis, MD PhD
Contact
stavros.chrysidis@rsyd.dk
0045 79 40 67 41
Nikoletta Svendsen, MD MSc
Contact
nikoletta.svendsen@rsyd.dk
0045 73 65 40 30
Stavros Chrysidis, MD PhD
principal investigator · University of Southern Denmark
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion